Cytori Therapeutics (CYTX) Stock Price Down 7.5%
Cytori Therapeutics Inc (NASDAQ:CYTX)’s share price dropped 7.5% on Friday . The stock traded as low as $0.24 and last traded at $0.24. Approximately 582,010 shares changed hands during trading, an increase of 2% from the average daily volume of 572,150 shares. The stock had previously closed at $0.26.
CYTX has been the subject of several recent research reports. Zacks Investment Research raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Maxim Group reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Monday, December 3rd.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Barclays PLC increased its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 724.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,747 shares of the biotechnology company’s stock after purchasing an additional 87,647 shares during the period. Barclays PLC owned 0.76% of Cytori Therapeutics worth $29,000 as of its most recent SEC filing. 3.10% of the stock is owned by hedge funds and other institutional investors.
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Featured Article: Earnings Per Share
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.